Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Br J Cancer ; 118(1): 43-51, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29112683

RESUMEN

BACKGROUND: Although altered membrane physiology has been discussed within the context of cancer, targeting membrane characteristics by drugs being an attractive therapeutic strategy has received little attention so far. METHODS: Various acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) inhibitors (like Soraphen A and Cerulenin) as well as genetic knockdown approaches were employed to study the effects of disturbed phospholipid composition on membrane properties and its functional impact on cancer progression. By using state-of-the-art methodologies such as LC-MS/MS, optical tweezers measurements of giant plasma membrane vesicles and fluorescence recovery after photobleaching analysis, membrane characteristics were examined. Confocal laser scanning microscopy, proximity ligation assays, immunoblotting as well as migration, invasion and proliferation experiments unravelled the functional relevance of membrane properties in vitro and in vivo. RESULTS: By disturbing the deformability and lateral fluidity of cellular membranes, the dimerisation, localisation and recycling of cancer-relevant transmembrane receptors is compromised. Consequently, impaired activation of growth factor receptor signalling cascades results in abrogated tumour growth and metastasis in different in vitro and in vivo models. CONCLUSIONS: This study highlights the field of membrane properties as a promising druggable cellular target representing an innovative strategy for development of anti-cancer agents.


Asunto(s)
Acetil-CoA Carboxilasa/genética , Inhibidores Enzimáticos/administración & dosificación , Acido Graso Sintasa Tipo I/genética , Lipogénesis/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Acetil-CoA Carboxilasa/antagonistas & inhibidores , Línea Celular Tumoral , Membrana Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Proliferación Celular , Cerulenina/administración & dosificación , Cerulenina/farmacología , Inhibidores Enzimáticos/farmacología , Acido Graso Sintasa Tipo I/antagonistas & inhibidores , Técnicas de Silenciamiento del Gen , Humanos , Macrólidos/administración & dosificación , Macrólidos/farmacología , Fluidez de la Membrana/efectos de los fármacos , Terapia Molecular Dirigida , Invasividad Neoplásica , Neoplasias/metabolismo , Fosfolípidos/análisis , Fotoblanqueo , Ensayos Antitumor por Modelo de Xenoinjerto
2.
Adv Healthc Mater ; 6(2)2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27863166

RESUMEN

Metal-organic frameworks (MOFs) are promising platforms for the synthesis of nanoparticles for diverse medical applications. Their fundamental design principles allow for significant control of the framework architecture and pore chemistry, enabling directed functionalization for nanomedical applications. However, before applying novel nanomaterials to patients, it is imperative to understand their potential health risks. In this study, the nanosafety of different MOF nanoparticles is analyzed comprehensively for diverse medical applications. The authors first evaluate the effects of MOFs on human endothelial and mouse lung cells, which constitute a first line of defense upon systemic blood-mediated and local lung-specific applications of nanoparticles. Second, we validated these MOFs for multifunctional surface coatings of dental implants using human gingiva fibroblasts. Moreover, biocompatibility of MOFs is assessed for surface coating of nerve guidance tubes using human Schwann cells and rat dorsal root ganglion cultures. The main finding of this study is that the nanosafety and principal suitability of our MOF nanoparticles as novel agents for drug delivery and implant coatings strongly varies with the effector cell type. We conclude that it is therefore necessary to carefully evaluate the nanosafety of MOF nanomaterials with respect to their particular medical application and their interacting primary cell types, respectively.


Asunto(s)
Portadores de Fármacos/química , Células Endoteliales/metabolismo , Fibroblastos/metabolismo , Encía/metabolismo , Nanopartículas/química , Animales , Portadores de Fármacos/efectos adversos , Células Endoteliales/citología , Fibroblastos/citología , Encía/citología , Humanos , Ratones , Nanopartículas/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA